What is a stock summary page? Click here for an overview.
Business Description
Orthocell Ltd
ISIN : AU000000OCC6
Description
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir which is a collagen wrap used in peripheral nerve repair; and OrthoACI an implantation used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline such as Tendon Cell Therapy and Collagen Medical Device Platform.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 46.87 | |||||
| Equity-to-Asset | 0.49 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 5.52 | |||||
| Beneish M-Score | -2.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 73.2 | |||||
| 3-Year EBITDA Growth Rate | 2.2 | |||||
| 3-Year EPS without NRI Growth Rate | 8.5 | |||||
| 3-Year FCF Growth Rate | -12.5 | |||||
| 3-Year Book Growth Rate | -37.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 82.28 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.78 | |||||
| 9-Day RSI | 38.64 | |||||
| 14-Day RSI | 43.75 | |||||
| 3-1 Month Momentum % | -1.59 | |||||
| 6-1 Month Momentum % | 157.29 | |||||
| 12-1 Month Momentum % | 197.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.53 | |||||
| Quick Ratio | 7.31 | |||||
| Cash Ratio | 6.36 | |||||
| Days Inventory | 195.71 | |||||
| Days Sales Outstanding | 114.9 | |||||
| Days Payable | 239.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.2 | |||||
| Shareholder Yield % | -4.76 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.19 | |||||
| Operating Margin % | -180.65 | |||||
| Net Margin % | -51.17 | |||||
| FCF Margin % | -127.22 | |||||
| ROE % | -36.97 | |||||
| ROA % | -10.64 | |||||
| ROIC % | -53.84 | |||||
| 3-Year ROIIC % | 23.89 | |||||
| ROC (Joel Greenblatt) % | -419.44 | |||||
| ROCE % | -44.83 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 46.83 | |||||
| PB Ratio | 17.13 | |||||
| Price-to-Tangible-Book | 16.75 | |||||
| EV-to-EBIT | -25.66 | |||||
| EV-to-EBITDA | -26.93 | |||||
| EV-to-Revenue | 46.34 | |||||
| EV-to-FCF | -38.38 | |||||
| Price-to-GF-Value | 0.91 | |||||
| Price-to-Median-PS-Value | 1.03 | |||||
| Price-to-Net-Current-Asset-Value | 19.14 | |||||
| Price-to-Net-Cash | 33.5 | |||||
| Earnings Yield (Greenblatt) % | -3.9 | |||||
| FCF Yield % | -2.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Orthocell Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 6.345 | ||
| EPS (TTM) (A$) | -0.016 | ||
| Beta | 0.14 | ||
| 3-Year Sharpe Ratio | 0.91 | ||
| 3-Year Sortino Ratio | 2.64 | ||
| Volatility % | 82.79 | ||
| 14-Day RSI | 43.75 | ||
| 14-Day ATR (A$) | 0.114102 | ||
| 20-Day SMA (A$) | 1.42225 | ||
| 12-1 Month Momentum % | 197.59 | ||
| 52-Week Range (A$) | 0.35 - 1.79 | ||
| Shares Outstanding (Mil) | 241.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Orthocell Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Orthocell Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Orthocell Ltd Frequently Asked Questions
What is Orthocell Ltd(ASX:OCC)'s stock price today?
The current price of ASX:OCC is A$1.34. The 52 week high of ASX:OCC is A$1.79 and 52 week low is A$0.35.
When is next earnings date of Orthocell Ltd(ASX:OCC)?
The next earnings date of Orthocell Ltd(ASX:OCC) is .
Does Orthocell Ltd(ASX:OCC) pay dividends? If so, how much?
Orthocell Ltd(ASX:OCC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers